NgFUS + Nivolumab for Brain Cancer

This trial explores a new treatment combination for individuals with certain recurring brain tumors. It uses nivolumab, an immunotherapy drug, alongside NeuroNavigation-Guided Focused Ultrasound (NgFUS). This technique temporarily opens the blood-brain barrier, the brain's protective filter, using ultrasound and microbubbles. The trial aims to determine the safety and practicality of this method for patients with diffuse midline glioma in the brainstem or other high-grade brain tumors requiring surgery. Individuals dealing with these specific tumor types that have returned or worsened might be suitable candidates for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative approach.

Earlier studies have shown that focused ultrasound (FUS) can safely open the blood-brain barrier. This barrier protects the brain from harmful substances but also blocks some helpful treatments. By using FUS to open it, medications can reach brain tumors more effectively. Although there are some risks, this method is generally considered safe.

Research indicates that nivolumab is well-tolerated by patients with primary brain tumors, including gliomas. While it hasn't consistently improved survival in certain brain cancers, it has been safely used in other studies with patients who have similar conditions.

Unlike the standard treatments for brain cancer, which often involve chemotherapy and radiation, this trial combines Nivolumab with NgFUS (nanoparticle-guided focused ultrasound) to potentially enhance its effectiveness. Nivolumab is an immunotherapy that works by activating the body's immune system to attack cancer cells, while NgFUS aims to temporarily open the blood-brain barrier, allowing for better delivery of the drug to the tumor. Researchers are excited about this approach because it could improve the precision and impact of treatment, offering new hope for patients with challenging brain tumors.

Research has shown that focused ultrasound, such as the NgFUS used in this trial, can help open the blood-brain barrier, allowing treatments to reach brain tumors more easily. This trial includes two groups: Group A, where patients with relapsed or progressive diffuse midline glioma in the brainstem receive Nivolumab with NgFUS either every 2 weeks or every 4 weeks, and Group B, where patients with relapsed or progressive high-grade brain tumors requiring surgical resection receive one dose of NgFUS before surgery, followed by Nivolumab with NgFUS every 4 weeks after recovery.